MX2011004052A - Composiciones farmaceuticas topicas. - Google Patents
Composiciones farmaceuticas topicas.Info
- Publication number
- MX2011004052A MX2011004052A MX2011004052A MX2011004052A MX2011004052A MX 2011004052 A MX2011004052 A MX 2011004052A MX 2011004052 A MX2011004052 A MX 2011004052A MX 2011004052 A MX2011004052 A MX 2011004052A MX 2011004052 A MX2011004052 A MX 2011004052A
- Authority
- MX
- Mexico
- Prior art keywords
- component
- composition according
- infections
- topical
- topical stable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 230000000699 topical effect Effects 0.000 title claims abstract description 38
- 239000006071 cream Substances 0.000 claims abstract description 69
- 239000002674 ointment Substances 0.000 claims abstract description 40
- 208000015181 infectious disease Diseases 0.000 claims description 46
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 36
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 32
- 239000000194 fatty acid Substances 0.000 claims description 32
- 229930195729 fatty acid Natural products 0.000 claims description 32
- -1 fatty acid esters Chemical class 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- XPIJWUTXQAGSLK-UHFFFAOYSA-N ozenoxacin Chemical compound C1=C(C)C(NC)=NC=C1C1=CC=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C XPIJWUTXQAGSLK-UHFFFAOYSA-N 0.000 claims description 30
- 229950011011 ozenoxacin Drugs 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 29
- 150000004665 fatty acids Chemical class 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 25
- 150000002191 fatty alcohols Chemical class 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 17
- 239000001993 wax Substances 0.000 claims description 17
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 16
- 125000005456 glyceride group Chemical group 0.000 claims description 14
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 12
- 238000002844 melting Methods 0.000 claims description 12
- 230000008018 melting Effects 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000000969 carrier Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 230000008029 eradication Effects 0.000 claims description 10
- 239000012188 paraffin wax Substances 0.000 claims description 10
- 229960004063 propylene glycol Drugs 0.000 claims description 10
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000005711 Benzoic acid Substances 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 235000010233 benzoic acid Nutrition 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 208000007313 Reproductive Tract Infections Diseases 0.000 claims description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 7
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 6
- 235000021313 oleic acid Nutrition 0.000 claims description 6
- 210000005000 reproductive tract Anatomy 0.000 claims description 6
- 229940100242 glycol stearate Drugs 0.000 claims description 5
- 150000002889 oleic acids Chemical class 0.000 claims description 5
- 229940119519 peg-32 stearate Drugs 0.000 claims description 5
- 229940119517 peg-6 stearate Drugs 0.000 claims description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- 229920000059 polyethylene glycol stearate Polymers 0.000 claims description 5
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 4
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims description 4
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 claims description 4
- MFKRHJVUCZRDTF-UHFFFAOYSA-N 3-methoxy-3-methylbutan-1-ol Chemical compound COC(C)(C)CCO MFKRHJVUCZRDTF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 229940051250 hexylene glycol Drugs 0.000 claims description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229940100615 topical ointment Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 229940124307 fluoroquinolone Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 18
- 239000000902 placebo Substances 0.000 description 18
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 14
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 13
- 229960003128 mupirocin Drugs 0.000 description 13
- 229930187697 mupirocin Natural products 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 12
- 150000001298 alcohols Chemical class 0.000 description 12
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 12
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 9
- 241000191963 Staphylococcus epidermidis Species 0.000 description 9
- 229960003085 meticillin Drugs 0.000 description 9
- 239000001979 cystine lactose electrolyte deficient agar Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 6
- 229960003405 ciprofloxacin Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 description 5
- 241000606768 Haemophilus influenzae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 229940047650 haemophilus influenzae Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 4
- 102100038816 Neuronatin Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 4
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 229960001915 hexamidine Drugs 0.000 description 4
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010016936 Folliculitis Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010021531 Impetigo Diseases 0.000 description 3
- 241000589248 Legionella Species 0.000 description 3
- 241000589242 Legionella pneumophila Species 0.000 description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 241000204048 Mycoplasma hominis Species 0.000 description 3
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 241000194005 Streptococcus sp. 'group G' Species 0.000 description 3
- 241000202921 Ureaplasma urealyticum Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000003512 furunculosis Diseases 0.000 description 3
- 229940115932 legionella pneumophila Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 150000007660 quinolones Chemical class 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- MGAXYKDBRBNWKT-UHFFFAOYSA-N (5-oxooxolan-2-yl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1OC(=O)CC1 MGAXYKDBRBNWKT-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 2
- VSHIRTNKIXRXMI-UHFFFAOYSA-N 2,2-dimethyl-1,3-oxazolidine Chemical compound CC1(C)NCCO1 VSHIRTNKIXRXMI-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- GJEULMGGGBFACC-UHFFFAOYSA-N 2-[2-(carboxymethylamino)ethylamino]ethyl-dodecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[NH2+]CCNCCNCC(O)=O GJEULMGGGBFACC-UHFFFAOYSA-N 0.000 description 2
- OUMYGJVUBNSAFG-PLKIVWSFSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;(2e,4e)-hexa-2,4-dienoic acid Chemical compound C\C=C\C=C\C(O)=O.OCCN(CCO)CCO OUMYGJVUBNSAFG-PLKIVWSFSA-N 0.000 description 2
- KWIPUXXIFQQMKN-UHFFFAOYSA-N 2-azaniumyl-3-(4-cyanophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-UHFFFAOYSA-N 0.000 description 2
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- GGPOVLCFVFOVDF-UHFFFAOYSA-N 2-phenoxyethyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCCOC1=CC=CC=C1 GGPOVLCFVFOVDF-UHFFFAOYSA-N 0.000 description 2
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 2
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 2
- XJJROVKTVSNUOG-UHFFFAOYSA-N 4-[6-(4-carbamimidoylphenoxy)hexoxy]benzenecarboximidamide 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1.OC(=O)C1=CC=C(O)C=C1.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 XJJROVKTVSNUOG-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- NFJHKCJICHOFRZ-UHFFFAOYSA-N 4-chloro-3-methylphenol;sodium Chemical compound [Na].CC1=CC(O)=CC=C1Cl NFJHKCJICHOFRZ-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 2
- ZYQIUVQBZWVFRE-UHFFFAOYSA-N 8-methylnonyl 4-hydroxybenzoate Chemical compound CC(C)CCCCCCCOC(=O)C1=CC=C(O)C=C1 ZYQIUVQBZWVFRE-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 2
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 2
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- KSQXVLVXUFHGJQ-UHFFFAOYSA-M Sodium ortho-phenylphenate Chemical compound [Na+].[O-]C1=CC=CC=C1C1=CC=CC=C1 KSQXVLVXUFHGJQ-UHFFFAOYSA-M 0.000 description 2
- 239000004283 Sodium sorbate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940090948 ammonium benzoate Drugs 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- XJMWHXZUIGHOBA-UHFFFAOYSA-N azane;propanoic acid Chemical compound N.CCC(O)=O XJMWHXZUIGHOBA-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- 229940034794 benzylparaben Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 235000010237 calcium benzoate Nutrition 0.000 description 2
- 239000004301 calcium benzoate Substances 0.000 description 2
- 235000010331 calcium propionate Nutrition 0.000 description 2
- 239000004330 calcium propionate Substances 0.000 description 2
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 2
- 235000010244 calcium sorbate Nutrition 0.000 description 2
- 239000004303 calcium sorbate Substances 0.000 description 2
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 2
- DTFQOFKRUDOJCR-UHFFFAOYSA-L calcium;4-carboxyphenolate Chemical compound [Ca+2].OC1=CC=C(C([O-])=O)C=C1.OC1=CC=C(C([O-])=O)C=C1 DTFQOFKRUDOJCR-UHFFFAOYSA-L 0.000 description 2
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 2
- 229960001884 chlorhexidine diacetate Drugs 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 229960005443 chloroxylenol Drugs 0.000 description 2
- 229960003993 chlorphenesin Drugs 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 150000001934 cyclohexanes Chemical class 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 150000001983 dialkylethers Chemical class 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IHDIFQKZWSOIBB-UHFFFAOYSA-M dodecyl-[(4-ethylphenyl)methyl]-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=C(CC)C=C1 IHDIFQKZWSOIBB-UHFFFAOYSA-M 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- ATJVZXXHKSYELS-FNORWQNLSA-N ethyl (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(O)C(OC)=C1 ATJVZXXHKSYELS-FNORWQNLSA-N 0.000 description 2
- 229940027504 ethyl ferulate Drugs 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- ATJVZXXHKSYELS-UHFFFAOYSA-N ferulic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=C(O)C(OC)=C1 ATJVZXXHKSYELS-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940113094 isopropylparaben Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- PJJZFXPJNUVBMR-UHFFFAOYSA-L magnesium benzoate Chemical compound [Mg+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 PJJZFXPJNUVBMR-UHFFFAOYSA-L 0.000 description 2
- CQQJGTPWCKCEOQ-UHFFFAOYSA-L magnesium dipropionate Chemical compound [Mg+2].CCC([O-])=O.CCC([O-])=O CQQJGTPWCKCEOQ-UHFFFAOYSA-L 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 108700019599 monomethylolglycine Proteins 0.000 description 2
- 229940074096 monoolein Drugs 0.000 description 2
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 235000010292 orthophenyl phenol Nutrition 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- 229940070805 p-chloro-m-cresol Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940106026 phenoxyisopropanol Drugs 0.000 description 2
- GJLNWLVPAHNBQN-UHFFFAOYSA-N phenyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OC1=CC=CC=C1 GJLNWLVPAHNBQN-UHFFFAOYSA-N 0.000 description 2
- FCJSHPDYVMKCHI-UHFFFAOYSA-N phenyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 235000010235 potassium benzoate Nutrition 0.000 description 2
- 239000004300 potassium benzoate Substances 0.000 description 2
- 229940103091 potassium benzoate Drugs 0.000 description 2
- 229960003191 potassium methylparaben Drugs 0.000 description 2
- BWILYWWHXDGKQA-UHFFFAOYSA-M potassium propanoate Chemical compound [K+].CCC([O-])=O BWILYWWHXDGKQA-UHFFFAOYSA-M 0.000 description 2
- 235000010332 potassium propionate Nutrition 0.000 description 2
- 239000004331 potassium propionate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- HFTYFFXNUVBSII-UHFFFAOYSA-M potassium;4-ethoxycarbonylphenolate Chemical compound [K+].CCOC(=O)C1=CC=C([O-])C=C1 HFTYFFXNUVBSII-UHFFFAOYSA-M 0.000 description 2
- DKGFIVSGQRBSOG-UHFFFAOYSA-M potassium;4-hydroxybenzoate Chemical compound [K+].OC1=CC=C(C([O-])=O)C=C1 DKGFIVSGQRBSOG-UHFFFAOYSA-M 0.000 description 2
- MOCBTMXJPWSHOD-UHFFFAOYSA-M potassium;4-methoxycarbonylphenolate Chemical compound [K+].COC(=O)C1=CC=C([O-])C=C1 MOCBTMXJPWSHOD-UHFFFAOYSA-M 0.000 description 2
- TUMYXYVXTFDMTJ-UHFFFAOYSA-M potassium;4-propoxycarbonylphenolate Chemical compound [K+].CCCOC(=O)C1=CC=C([O-])C=C1 TUMYXYVXTFDMTJ-UHFFFAOYSA-M 0.000 description 2
- ZGJADVGJIVEEGF-UHFFFAOYSA-M potassium;phenoxide Chemical compound [K+].[O-]C1=CC=CC=C1 ZGJADVGJIVEEGF-UHFFFAOYSA-M 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- PERLTXCUPZSJTA-YTXTXJHMSA-N propan-2-yl (2e,4e)-hexa-2,4-dienoate Chemical compound C\C=C\C=C\C(=O)OC(C)C PERLTXCUPZSJTA-YTXTXJHMSA-N 0.000 description 2
- ZSLXNNRJTBPGFJ-UHFFFAOYSA-N propan-2-yl 4-hydroxybenzoate;sodium Chemical compound [Na].CC(C)OC(=O)C1=CC=C(O)C=C1 ZSLXNNRJTBPGFJ-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229940095574 propionic acid Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 229940089970 quaternium-14 Drugs 0.000 description 2
- 229940096792 quaternium-15 Drugs 0.000 description 2
- UKHVLWKBNNSRRR-TYYBGVCCSA-M quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C/C=C/Cl)C3 UKHVLWKBNNSRRR-TYYBGVCCSA-M 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- ZLVSYODPTJZFMK-UHFFFAOYSA-M sodium 4-hydroxybenzoate Chemical compound [Na+].OC1=CC=C(C([O-])=O)C=C1 ZLVSYODPTJZFMK-UHFFFAOYSA-M 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 2
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 2
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000010294 sodium orthophenyl phenol Nutrition 0.000 description 2
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 2
- 235000019250 sodium sorbate Nutrition 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 2
- HLDPLHCMNIULPL-UHFFFAOYSA-M sodium;4-(2-methylpropoxycarbonyl)phenolate Chemical compound [Na+].CC(C)COC(=O)C1=CC=C([O-])C=C1 HLDPLHCMNIULPL-UHFFFAOYSA-M 0.000 description 2
- OGBHACNFHJJTQT-UHFFFAOYSA-M sodium;4-butoxycarbonylphenolate Chemical compound [Na+].CCCCOC(=O)C1=CC=C([O-])C=C1 OGBHACNFHJJTQT-UHFFFAOYSA-M 0.000 description 2
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 2
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 2
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 2
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 229960001325 triclocarban Drugs 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 229960002703 undecylenic acid Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940045860 white wax Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VXXGNCSYTUUGFW-UHFFFAOYSA-N 2-(dimethylamino)icosyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCC(N(C)C)COC(=O)C(C)=C VXXGNCSYTUUGFW-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- NKXINWNCBKRRIC-UHFFFAOYSA-N 2-methyl-3-propan-2-ylphenol Chemical class CC(C)C1=CC=CC(O)=C1C NKXINWNCBKRRIC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VFDASNWZZRLEAU-UHFFFAOYSA-N 3-bromo-4-[3-(2-bromo-4-carbamimidoylphenoxy)propoxy]benzenecarboximidamide;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br VFDASNWZZRLEAU-UHFFFAOYSA-N 0.000 description 1
- DOZFVXFONAPWPQ-UHFFFAOYSA-N 4-chlorosyl-5-methyl-5H-1,3-thiazol-2-one Chemical compound CC1C(=NC(S1)=O)Cl=O DOZFVXFONAPWPQ-UHFFFAOYSA-N 0.000 description 1
- 229940046305 5-bromo-5-nitro-1,3-dioxane Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- HIQJJDNYQIPIKB-UHFFFAOYSA-N C=C.C=C.NN(N)CC(O)=O Chemical compound C=C.C=C.NN(N)CC(O)=O HIQJJDNYQIPIKB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMQNKVGDYIXYDI-UHFFFAOYSA-N [Na].C=C.C=C Chemical group [Na].C=C.C=C FMQNKVGDYIXYDI-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000493 dibrompropamidine Drugs 0.000 description 1
- GMJFVGRUYJHMCO-UHFFFAOYSA-N dibrompropamidine Chemical compound BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br GMJFVGRUYJHMCO-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940115931 listeria monocytogenes Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- DPMDQHINTKFMKS-UHFFFAOYSA-M potassium;4-butoxycarbonylphenolate Chemical compound [K+].CCCCOC(=O)C1=CC=C([O-])C=C1 DPMDQHINTKFMKS-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229960002771 retapamulin Drugs 0.000 description 1
- STZYTFJPGGDRJD-NHUWBDDWSA-N retapamulin Chemical compound C([C@H]([C@@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CS[C@@H]3C[C@H]4CC[C@H](N4C)C3)C)C[C@]32[C@H]1C(=O)CC3 STZYTFJPGGDRJD-NHUWBDDWSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- UOULCEYHQNCFFH-UHFFFAOYSA-M sodium;hydroxymethanesulfonate Chemical compound [Na+].OCS([O-])(=O)=O UOULCEYHQNCFFH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- WVPSKSLAZQPAKQ-SOSAQKQKSA-N trovafloxacin Chemical compound C([C@H]1C([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-SOSAQKQKSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08166933A EP2177208A1 (en) | 2008-10-17 | 2008-10-17 | Pharmaceutical topical compositions |
| PCT/EP2009/063625 WO2010043717A2 (en) | 2008-10-17 | 2009-10-16 | Pharmaceutical topical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011004052A true MX2011004052A (es) | 2011-05-10 |
Family
ID=40291273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011004052A MX2011004052A (es) | 2008-10-17 | 2009-10-16 | Composiciones farmaceuticas topicas. |
| MX2013009409A MX338029B (es) | 2008-10-17 | 2009-10-16 | Composiciones farmaceuticas topicas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009409A MX338029B (es) | 2008-10-17 | 2009-10-16 | Composiciones farmaceuticas topicas. |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9180200B2 (enExample) |
| EP (3) | EP2177208A1 (enExample) |
| JP (2) | JP5509209B2 (enExample) |
| KR (3) | KR101682256B1 (enExample) |
| CN (1) | CN102186460B (enExample) |
| AR (1) | AR073901A1 (enExample) |
| AU (1) | AU2009305360B2 (enExample) |
| BR (1) | BRPI0920355B8 (enExample) |
| CA (2) | CA2738384C (enExample) |
| CL (2) | CL2011000848A1 (enExample) |
| CY (1) | CY1114838T1 (enExample) |
| DK (1) | DK2344130T3 (enExample) |
| ES (1) | ES2437967T3 (enExample) |
| MX (2) | MX2011004052A (enExample) |
| NL (1) | NL300884I2 (enExample) |
| PH (1) | PH12014502425A1 (enExample) |
| PL (1) | PL2344130T3 (enExample) |
| PT (1) | PT2344130E (enExample) |
| RU (1) | RU2478367C2 (enExample) |
| SI (1) | SI2344130T1 (enExample) |
| TW (2) | TWI504418B (enExample) |
| UY (1) | UY32187A (enExample) |
| WO (1) | WO2010043717A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130070608A (ko) | 2010-05-10 | 2013-06-27 | 세게티스, 인코포레이티드. | 미립자 고체에 대한 분산제 및 슬립제로서의 알킬 케탈 에스터 및 그의 제조방법, 및 용도 |
| WO2014047428A1 (en) | 2012-09-21 | 2014-03-27 | Segetis, Inc. | Cleaning, surfactant, and personal care compositions |
| DE102013226507B4 (de) * | 2013-12-18 | 2022-05-05 | Ashland Industries Europe Gmbh | Konzentrat umfassend Ferulasäureethylester und Arylalkanol und dessen Verwendung |
| ES2661000T3 (es) * | 2014-09-12 | 2018-03-27 | Antibiotx A/S | Uso antibacteriano de salicilanilidas halogenadas |
| EP3257512A4 (en) * | 2015-02-13 | 2018-07-25 | Maruho Co., Ltd. | External preparation comprising pyridonecarboxylic acid derivative |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| JP7347915B2 (ja) * | 2016-04-28 | 2023-09-20 | マルホ株式会社 | 抗菌剤 |
| WO2018048042A1 (ko) * | 2016-09-12 | 2018-03-15 | 주식회사 가나씨앤에이치 | 글리세린 젖산 에스테르를 유효성분으로 하는 방부 및 항균용 외용제 조성물 |
| EP3549586A1 (en) * | 2016-12-01 | 2019-10-09 | Maruho Co., Ltd. | Medical skin external preparation |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| CN113712913A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 一种奥泽沙星混悬滴眼液组合物 |
| US11724077B2 (en) * | 2021-07-28 | 2023-08-15 | Subhash Dhawan | Therapeutic swabs for treating upper respiratory infections |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04243827A (ja) * | 1991-01-25 | 1992-08-31 | Sumitomo Pharmaceut Co Ltd | プロスタグランジン誘導体含有溶解型軟膏剤 |
| JP3174590B2 (ja) * | 1991-04-04 | 2001-06-11 | テルモ株式会社 | ステロイド軟膏剤 |
| FR2728166A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
| JP3162335B2 (ja) * | 1998-03-11 | 2001-04-25 | ユーナイテッド ネイションズ デベロップメント プログラム | 皮膚真菌感染症治療用の植物薬剤、その製造法と用途 |
| ATE342897T1 (de) | 1998-04-06 | 2006-11-15 | Toyama Chemical Co Ltd | Chinoloncarbonsäurederivate oder deren salze |
| GB0013674D0 (en) * | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| JP4293755B2 (ja) | 2001-03-26 | 2009-07-08 | 富山化学工業株式会社 | ピリドンカルボン酸系化合物を含有する皮膚外用剤 |
| JP4384402B2 (ja) | 2001-11-30 | 2009-12-16 | 富山化学工業株式会社 | デスフルオロピリドンカルボン酸系化合物を含有する水溶液剤およびその粉末化物並びにそれら製造方法 |
| PL1731138T3 (pl) | 2004-03-31 | 2016-10-31 | Drobnoziarnista dyspersja słabo rozpuszczalnego leku i sposób jej wytwarzania | |
| EP1698336A1 (en) * | 2005-03-01 | 2006-09-06 | Ferrer Internacional, S.A. | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent |
| ES2553179T3 (es) | 2005-08-01 | 2015-12-04 | Maruho Co., Ltd. | Preparación de una loción que contiene un derivado del ácido piridoncarboxílico |
| JP5112669B2 (ja) | 2005-09-30 | 2013-01-09 | 富山化学工業株式会社 | 難溶性薬物のナノ微粒子を含有する水性懸濁液剤 |
-
2008
- 2008-10-17 EP EP08166933A patent/EP2177208A1/en not_active Withdrawn
-
2009
- 2009-10-16 RU RU2011119764/15A patent/RU2478367C2/ru active
- 2009-10-16 PL PL09736946T patent/PL2344130T3/pl unknown
- 2009-10-16 US US13/124,403 patent/US9180200B2/en active Active
- 2009-10-16 JP JP2011531512A patent/JP5509209B2/ja not_active Expired - Fee Related
- 2009-10-16 DK DK09736946.6T patent/DK2344130T3/da active
- 2009-10-16 CA CA2738384A patent/CA2738384C/en active Active
- 2009-10-16 EP EP09736946.6A patent/EP2344130B9/en active Active
- 2009-10-16 KR KR1020117008243A patent/KR101682256B1/ko active Active
- 2009-10-16 KR KR1020167026446A patent/KR20160116353A/ko not_active Ceased
- 2009-10-16 ES ES09736946.6T patent/ES2437967T3/es active Active
- 2009-10-16 MX MX2011004052A patent/MX2011004052A/es active IP Right Grant
- 2009-10-16 CA CA2822167A patent/CA2822167C/en not_active Expired - Fee Related
- 2009-10-16 KR KR1020167003529A patent/KR20160025034A/ko not_active Ceased
- 2009-10-16 BR BRPI0920355A patent/BRPI0920355B8/pt not_active IP Right Cessation
- 2009-10-16 SI SI200930749T patent/SI2344130T1/sl unknown
- 2009-10-16 CN CN2009801408602A patent/CN102186460B/zh active Active
- 2009-10-16 WO PCT/EP2009/063625 patent/WO2010043717A2/en not_active Ceased
- 2009-10-16 PT PT97369466T patent/PT2344130E/pt unknown
- 2009-10-16 EP EP12192559A patent/EP2570117A1/en not_active Withdrawn
- 2009-10-16 MX MX2013009409A patent/MX338029B/es unknown
- 2009-10-16 AU AU2009305360A patent/AU2009305360B2/en not_active Ceased
- 2009-10-19 AR ARP090104005A patent/AR073901A1/es unknown
- 2009-10-19 UY UY0001032187A patent/UY32187A/es active IP Right Grant
- 2009-10-19 TW TW098135341A patent/TWI504418B/zh not_active IP Right Cessation
- 2009-10-19 TW TW103134727A patent/TW201511779A/zh unknown
-
2011
- 2011-04-15 CL CL2011000848A patent/CL2011000848A1/es unknown
-
2013
- 2013-12-03 CY CY20131101082T patent/CY1114838T1/el unknown
-
2014
- 2014-02-21 JP JP2014031852A patent/JP5873120B2/ja not_active Expired - Fee Related
- 2014-03-05 US US14/197,933 patent/US9399014B2/en active Active
- 2014-10-29 PH PH12014502425A patent/PH12014502425A1/en unknown
-
2015
- 2015-09-29 CL CL2015002899A patent/CL2015002899A1/es unknown
- 2015-10-14 US US14/882,818 patent/US20160030338A1/en not_active Abandoned
-
2016
- 2016-05-04 US US15/146,461 patent/US10022363B2/en active Active
-
2017
- 2017-07-11 NL NL300884C patent/NL300884I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10022363B2 (en) | Pharmaceutical topical compositions | |
| AU709478B2 (en) | Otic microbial combinations | |
| EP1539155B1 (de) | Stabile creme-zubereitungen von phenyl-pyridonverbindungen für topische anwendung | |
| TW200939956A (en) | Agent for controlling post-harvest disease and method for controlling post-harvest disease | |
| MXPA96006361A (es) | Combinacionesóticas microbianas | |
| HK1161552B (en) | Pharmaceutical topical compositions | |
| CN1501814A (zh) | 药物组合物 | |
| JP2012162480A (ja) | メチシリン耐性黄色ブドウ球菌用抗菌剤 | |
| HK1069539A (en) | Otic microbial combinations for treatment of animals with ruptured tympanic membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |